非小細胞肺がんに対するCarboplatin+weekly Paclitaxel併用療法の初回用量減量による副作用軽減効果の検証

概要

論文の詳細を見る
At Kanazawa Medical University Hospital,all patients with advanced non-small-cell lung cancer (NSCLC) are treated with a standardized regimen including carboplatin (CBDCA) plus paclitaxel (PTX) chemotherapy.However,the initial dosage setting is left to the judgment of each doctor,and a standardized protocol for dosage reduction has not been established.In this study,therefore,we examined initial dosage settings and adverse effect frequencies in 34 NSCLC patients treated with CBDCA/PTX chemotherapy,to see whether standardization of dose reduction would be possible.The initial dosage setting of CBDCA and/or PTX had been reduced in 20 NSCLC patients (58.8%).Since the difference between the standard and actual dose of PTX increases with age (y=0.56 x-22.75,r2=0.23,p<0.01),each doctor had reduced the dosage according to the patient's age.When the incidence of hematologic toxicities was compared between patients under and over the age of 70,the incidence of neutropenia was significantly higher in the latter (p=0.035).The incidence of grade 3 or 4 neutropenia was significantly higher in the patients treated with the standard PTX dose than in those treated with a reduced PTX dose (p=0.034).In this study,we noted that there was not only a need to validate the initial dosage setting in CBDCA/PTX chemotherapy,but also a need to improve certain points.Our findings suggest that a standardized method for calculating initial dosage settings should be established through discussion of the data we obtained.
日本医療薬学会の論文

非小細胞肺がんに対するCarboplatin+weekly Paclitaxel併用療法の初回用量減量による副作用軽減効果の検証

スポンサーリンク

概要

著者

関連論文

スポンサーリンク